\-\ Texto\\:\\ \ \(0\)\
\-\ disoriented\\ x\\ 3\ \(1\)\
\-\ supportive\\ with\\ medrol\\ dose\\ pack\\ and\\ dilantin\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ high\\ signal\\ intensity\\ on\\ t2\\ and\\ flair\\ sequences\\ in\\ the\\ posterior\\ temporal\\ and\\ occipital\\ lobes\\ on\\ the\\ left\\.\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ leptomeningeal\\ enhancement\\ in\\ same\\ location\\ following\\ contrast\\ administration\\.\ \(0\)\
\-\ cns\\ vasculitis\ \(0\)\
\-\ \\â\\€\\¢\\ meningtitis\\/encephalitis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ leptomeningeal\\ tumor\\ spread\ \(0\)\
\-\ \\â\\€\\¢\\ vasculitis\ \(1\)\
\-\ 55\\ year\\ old\\ alcoholic\\ woman\\ was\\ admitted\\ to\\ hospital\\ with\\ confusion\\ and\\ delirium\\.\\ \\ preliminary\\ diagnosis\\ was\\ wernicke\\ encephalopathy\ \(0\)\
\-\ pathology\\ report\\ on\\ brain\\ biopsy\\ is\\ as\\ follows\\:\ \(0\)\
\-\ localized\\ cortical\\ vascular\\ abnormalities\\ \\(cannot\\ exclude\\ vasculitis\\)\\ \\ associated\\ selective\\ neuronal\\ necrosis\\ and\\ minor\\ phagocytic\\ reaction\\ \\ \ \(0\)\
\-\ no\\ evidence\\ of\\ meningeal\\ infiltration\\,\\ neoplasm\\,\\ granulomatous\\ reaction\\,\\ viral\\ \\ cytopathologic\\ effects\\,\\ or\\ acute\\ inflammation\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vasculitis\\:\\ 0\\.11117458900363174\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.08606523399462931\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.07967869584385871\ \(0\)\
\-\ meningtitis\\/encephalitis\\:\\ 0\\.07470778325395337\ \(0\)\
\-\ delirium\\:\\ 0\\.06883365460514028\ \(0\)\
\-\ phagocytic\\:\\ 0\\.06883365460514028\ \(0\)\
\-\ reaction\\:\\ 0\\.06578041509891197\ \(0\)\
\-\ cytopathologic\\:\\ 0\\.06539750962117279\ \(0\)\
\-\ medrol\\:\\ 0\\.06295952595632719\ \(0\)\
\-\ wernicke\\:\\ 0\\.06106847891129151\ \(0\)\
\-\ dilantin\\:\\ 0\\.05708539730751409\ \(0\)\
\-\ preliminary\\:\\ 0\\.05608723598839219\ \(0\)\
\-\ alcoholic\\:\\ 0\\.05364925232354659\ \(0\)\
\-\ disoriented\\:\\ 0\\.05121126865870099\ \(0\)\
\-\ neuronal\\:\\ 0\\.05121126865870099\ \(0\)\
\-\ selective\\:\\ 0\\.049754910549153035\ \(0\)\
\-\ meningeal\\:\\ 0\\.046171377915084945\ \(0\)\
\-\ pack\\:\\ 0\\.04588407662969782\ \(0\)\
\-\ confusion\\:\\ 0\\.04344609296485222\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.04263837957667997\ \(0\)\
\-\ effects\\:\\ 0\\.042261669724384776\ \(0\)\
\-\ abnormal\\:\\ 0\\.0413066481409307\ \(0\)\
\-\ infiltration\\:\\ 0\\.039463011361074794\ \(0\)\
\-\ follows\\:\\ 0\\.038949243379579584\ \(0\)\
\-\ exclude\\:\\ 0\\.03846485004195291\ \(0\)\
\-\ dose\\:\\ 0\\.037895872899261135\ \(0\)\
\-\ minor\\:\\ 0\\.03715848834850156\ \(0\)\
\-\ cns\\:\\ 0\\.037058196334543915\ \(0\)\
\-\ viral\\:\\ 0\\.036480160317369906\ \(0\)\
\-\ localized\\:\\ 0\\.035267441303465895\ \(0\)\
\-\ 55\\:\\ 0\\.035107538894106706\ \(0\)\
\-\ spread\\:\\ 0\\.03502870505798541\ \(0\)\
\-\ granulomatous\\:\\ 0\\.034950597811333514\ \(0\)\
\-\ occipital\\:\\ 0\\.03378987022596777\ \(0\)\
\-\ flair\\:\\ 0\\.033200666305216835\ \(0\)\
\-\ report\\:\\ 0\\.03241598167108273\ \(0\)\
\-\ supportive\\:\\ 0\\.03202174425044804\ \(0\)\
\-\ lobes\\:\\ 0\\.03191239336200814\ \(0\)\
\-\ admitted\\:\\ 0\\.031284359699688465\ \(0\)\
\-\ inflammation\\:\\ 0\\.030794363336223842\ \(0\)\
\-\ sequences\\:\\ 0\\.03024147755767807\ \(0\)\
\-\ administration\\:\\ 0\\.030064917499179406\ \(0\)\
\-\ same\\:\\ 0\\.02984926779018649\ \(0\)\
\-\ pathology\\:\\ 0\\.029638969746799\ \(0\)\
\-\ temporal\\:\\ 0\\.02899907523401811\ \(0\)\
\-\ necrosis\\:\\ 0\\.02858559926648055\ \(0\)\
\-\ hospital\\:\\ 0\\.02726352936413664\ \(0\)\
\-\ abnormalities\\:\\ 0\\.02659970018388319\ \(0\)\
\-\ cortical\\:\\ 0\\.02639893941165942\ \(0\)\
\-\ intensity\\:\\ 0\\.0261751752235534\ \(0\)\
\-\ biopsy\\:\\ 0\\.02569231560709119\ \(0\)\
\-\ location\\:\\ 0\\.025260234634778753\ \(0\)\
\-\ neoplasm\\:\\ 0\\.024662343863660407\ \(0\)\
\-\ x\\:\\ 0\\.02389039267243625\ \(0\)\
\-\ vascular\\:\\ 0\\.023744095490878785\ \(0\)\
\-\ brain\\:\\ 0\\.021791114604260694\ \(0\)\
\-\ lymphoma\\:\\ 0\\.020696598596521065\ \(0\)\
\-\ following\\:\\ 0\\.02055320132967075\ \(0\)\
\-\ t2\\:\\ 0\\.020496514989409763\ \(0\)\
\-\ high\\:\\ 0\\.019818186958278097\ \(0\)\
\-\ enhancement\\:\\ 0\\.01941092174680539\ \(0\)\
\-\ signal\\:\\ 0\\.019093850256548972\ \(0\)\
\-\ evidence\\:\\ 0\\.01898680155395659\ \(0\)\
\-\ on\\:\\ 0\\.018404008788951563\ \(0\)\
\-\ acute\\:\\ 0\\.017880333297512672\ \(0\)\
\-\ associated\\:\\ 0\\.01708866577887883\ \(0\)\
\-\ 3\\:\\ 0\\.016957419717852033\ \(0\)\
\-\ tumor\\:\\ 0\\.01688332458992213\ \(0\)\
\-\ was\\:\\ 0\\.01675046647819808\ \(0\)\
\-\ woman\\:\\ 0\\.01672799108041446\ \(0\)\
\-\ posterior\\:\\ 0\\.01669185210764787\ \(0\)\
\-\ diagnosis\\:\\ 0\\.016628977379495084\ \(0\)\
\-\ can\\:\\ 0\\.01642561315651754\ \(0\)\
\-\ contrast\\:\\ 0\\.016209963447524622\ \(0\)\
\-\ as\\:\\ 0\\.010954046660119727\ \(0\)\
\-\ not\\:\\ 0\\.010464565014762164\ \(0\)\
\-\ \\:\\:\\ 0\\.00957860013551411\ \(0\)\
\-\ \\,\\:\\ 0\\.009176612390416521\ \(0\)\
\-\ or\\:\\ 0\\.00848748092342125\ \(0\)\
\-\ left\\:\\ 0\\.008102587027736566\ \(0\)\
\-\ year\\:\\ 0\\.008102587027736566\ \(0\)\
\-\ and\\:\\ 0\\.007627500242890612\ \(0\)\
\-\ old\\:\\ 0\\.007414699973408937\ \(0\)\
\-\ no\\:\\ 0\\.00729189958223561\ \(0\)\
\-\ in\\:\\ 0\\.007142325934580592\ \(0\)\
\-\ \\(\\:\\ 0\\.006121709544439496\ \(0\)\
\-\ \\)\\:\\ 0\\.0060469295941805515\ \(0\)\
\-\ is\\:\\ 0\\.0047651760880061496\ \(0\)\
\-\ to\\:\\ 0\\.0036192212579914088\ \(0\)\
\-\ the\\:\\ 0\\.0023432082153156913\ \(0\)\
\-\ with\\:\\ 0\\.001983121628642199\ \(0\)\
\-\ of\\:\\ 0\\.0009873203457456646\ \(0\)\
\-\ \\.\\:\\ 0\\.0009025305787460918\ \(0\)\
